ER‐positive breast cancers are generally responsive to endocrine therapies, including those targeting oestrogen synthesis (aromatase inhibitors, AI), selective oestrogen receptor modulators (SERMs) like tamoxifen, and selective oestrogen receptor degraders (SERDs) like fulvestrant [3]. The gene discussed is CYP19A1; the disease is breast cancer.